US03209R1032 - Common Stock
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (11/21/2024, 8:12:10 PM)
After market: 44.55 0 (0%)44.55
+0.46 (+1.04%)
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 1,761 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
AMPHASTAR PHARMACEUTICALS IN
11570 6th St
Rancho Cucamonga CALIFORNIA 91730
P: 19099809484
CEO: Jack Y. Zhang
Employees: 1761
Website: https://amphastar.com/
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Here you can normally see the latest stock twits on AMPH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: